Hostname: page-component-54dcc4c588-dbm8p Total loading time: 0 Render date: 2025-10-13T10:12:41.388Z Has data issue: false hasContentIssue false
  • English
  • Français

Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker

Published online by Cambridge University Press:  14 July 2016

Esra Soydaş Akyol ,
Yakup Albayrak ,
Nurkan Aksoy ,
Başak Şahin ,
Murat Beyazyüz ,
Murat Kuloğlu  and
Kenji Hashimoto
Esra Soydaş Akyol
Affiliation:
Department of Psychiatry, Yenimahalle Education and Research Hospital, Ankara, Turkey
Yakup Albayrak*
Affiliation:
Department of Psychiatry, Faculty of Medicine, Namık Kemal University, Tekirdag, Turkey
Nurkan Aksoy
Affiliation:
Department of Biochemistry, Yenimahalle Education and Research Hospital, Ankara, Turkey
Başak Şahin
Affiliation:
Department of Psychiatry, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkey
Murat Beyazyüz
Affiliation:
Department of Psychiatry, Faculty of Medicine, Namık Kemal University, Tekirdag, Turkey
Murat Kuloğlu
Affiliation:
Department of Psychiatry, Faculty of Medicine, Akdeniz University, Antalya, Turkey
Kenji Hashimoto
Affiliation:
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
*
Yakup Albayrak, Department of Psychiatry, Faculty of Medicine, Namık Kemal University, Namık Kemal Universitesi Uygulama ve Arastırma Hastanesi Psikiyatri Poliklinigi, Yıl mah, Tekirdag, Turkey. Tel: +90 505 635 5434; Fax: +90 282 250 5924; E-mail: dr.fuge@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

The product of the G72 gene is an activator of d-amino acid oxidase and has been suggested to play a role in the pathogenesis of schizophrenia. Increased G72 protein levels may be associated with disturbed glutamatergic transmission and increased reactive oxygen species. Only one pilot study by Lin et al. has investigated the potential role of serum G72 protein levels as a biomarker for schizophrenia. In this study, we aimed to compare serum G72 protein levels between patients with schizophrenia and healthy controls, and to retest the results of the previous pilot study.

Materials and methods

In total, 107 patients with a diagnosis of schizophrenia according to the inclusion and exclusion criteria and 60 age–sex-matched healthy controls were included in the study. The groups were compared regarding serum G72 protein levels.

Results

The mean serum G72 protein values were 495.90±152.03 pg/ml in the schizophrenia group and 346.10±102.08 pg/ml in the healthy control group. The mean serum G72 protein level was significantly increased in the schizophrenia group compared with the healthy control group (t=−3.89, p<0.001). A receiver operating characteristics analysis was performed to compare the schizophrenia and healthy control groups. It was determined that the cut-off value was 141.51 pg/ml with a sensitivity of 0.991 and a specificity of 0.821.

Conclusion

We suggest that serum G72 protein levels may represent a candidate biomarker for schizophrenia and have confirmed the results of the previous preliminary study. Additional studies with larger sample sizes and the inclusion of first episode schizophrenia patients are required to clarify the reliability and validity of serum G72 protein levels as a biomarker for schizophrenia.

Keywords

biomarkerG72glutamateschizophrenia

Information

Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 29 , Issue 2 , April 2017 , pp. 80 - 86
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Insel, TR. Rethinking schizophrenia. Nature 2010;468:188–193.Google Scholar
2. Arnsten, AF, Wang, M, Paspalas, CD. Dopamine’s actions in primate prefrontal cortex: challenges for treating cognitive disorders. Pharmacol Rev 2015;67:681–696.Google Scholar
3. Javitt, DC. Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hillside J Clin Psychiatry 1987;9:12–35.Google Scholar
4. Ellaithy, A, Younkin, J, González-Maeso, J, Logothetis, DE. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci 2015;38:506–516.Google Scholar
5. Razafsha, M, Khaku, A, Azari, H, Alawieh, A, Behforuzi, H, Fadlallah, B. Biomarker identification in psychiatric disorders: from neuroscience to clinical practice. J Psychiatr Pract 2015;21:37–48.CrossRefGoogle ScholarPubMed
6. Boks, MP, Rietkerk, T, Van DE Beek, MH et al. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol 2007;17:567–572.Google Scholar
7. Chumakov, I, Blumenfeld, M, Guerassimenko, O, Cavarec, L, Palicio, M, Abderrahim, H. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675–13680.CrossRefGoogle ScholarPubMed
8. Labrie, V, Wong, AH, Roder, JC. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 2012;62:1484–1503.Google Scholar
9. Laruelle, M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol 2014;14:97–102.Google Scholar
10. Kvajo, M, Dhilla, A, Swor, DE, Karayiorgou, M, Gogos, JA. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 2008;13:685–696.CrossRefGoogle ScholarPubMed
11. Sacchi, S, Bernascon, M, Martineau, M et al. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem 2008;283:22244–22256.Google Scholar
12. Wang, M, Chen, HJ, Zhang, J, Li, W, XİE, X, Chang, HT. Identification of pLG72-induced oxidative stress using systemic approaches. Biomed Res Int 2015;2015:429253.Google Scholar
13. Lin, CH, Chang, HT, Chen, YJ et al. Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Mol Psychiatry 2014;19:636–637.Google Scholar
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Washington, DC: American Psychiatric Association, 2013.Google Scholar
15. Andreasen, NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: College of Medicine, University of Iowa, 1984.Google Scholar
16. Erkoç, S, Arkonaç, O, Atakli, C, Ozmen, E. The reliability and validity of scale for the assessment of negative symptoms. Düşünen Adam 1991;4:16–19 (in Turkish).Google Scholar
17. Andreasen, NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: College of Medicine, University of Iowa, 1984.Google Scholar
18. Erkoç, S, Arkonaç, O, Atakli, C, Ozmen, E. The reliability and validity of scale for the assessment of positive symptoms. Düşünen Adam 1991;4:20–24 (in Turkish).Google Scholar
19. Overall, JE, Gorham, DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.CrossRefGoogle Scholar
20. Jvitta, DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987;9:12–35.Google Scholar
21. Javitt, DC, Zukin, SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–1308.Google Scholar
22. Olney, JW, Farber, NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998–1007.Google Scholar
23. Coyle, JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241–253.Google Scholar
24. Krystal, JH, Karper, LP, Seibyl, JP, Freeman, GK, Delaney, R, Bremner, JD. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199–214.Google Scholar
25. Malhotra, AK, Pinals, DA, Adler, CM, Elman, I, Clifton, A, Pickar, D. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacol 1997;17:141–150.Google Scholar
26. Hu, W, Macdonald, ML, Elswick, DE, Sweet, RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 2015;1338:38–57.Google Scholar
27. Dalmau, J, Gleichman, AJ, Hughes, EG, Rossi, JE, Peng, X, Lai, M. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.Google Scholar
28. Hughes, EG, Peng, X, Gleichman, AJ, Lai, M, Zhou, L, Tsou, R. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.CrossRefGoogle ScholarPubMed
29. Balu, DT, Li, Y, Puhl, MD, Benneyworth, MA, Basu, AC, Takagi, S. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A 2013;110:E2400–E2409.CrossRefGoogle ScholarPubMed
30. Korostishevsky, M, Kaganovich, M, Cholostoy, A, Ashkenazi, M, Ratner, Y, Dahary, D. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004;56:169–176.Google Scholar
31. Mothet, JP, Parent, AT, Wolosker, H, Brady, RO Jr., Linden, DJ, Ferris, CD. D-serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Natl Acad Sci U S A 2000;97:4926–4931.CrossRefGoogle ScholarPubMed
32. Epstein, FH, Lipton, SA, Rosenberg, PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613–622.Google Scholar
33. Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742–755.Google Scholar
34. Sehgal, SA, Mannan, S, Kanwal, S, Naveed, I, Mir, A. Adaptive evolution and elucidating the potential inhibitor against schizophrenia to target DAOA (G72) isoforms. Drug Des Devel Ther 2015;3:3471–3480.Google Scholar
35. Hashimoto, K, Fukushima, T, Shimizu, E, Komatsu, N, Watanabe, H, Shinoda, N. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572–576.Google Scholar
36. Mitchell, J, Paul, P, Chen, HJ, Morris, A, Payling, M, Falchi, M. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A 2010;107:7556–7561.Google Scholar
37. Akibinu, MO, Ogundahunsi, O, Ogunyemi, EO. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 2012;5:169.CrossRefGoogle Scholar
38. Taneli, F, Pirildar, S, Akdeniz, F, Uyanik, BS, Ari, Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004;35:401–405.Google Scholar
39. Padurariu, M, Ciobica, A, Dobrin, I, Stefanescu, C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010;479:317–320.Google Scholar
40. Zhang, XY, Zhou, DF, Cao, LY, Zhang, PY, Wu, GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003;117:85–88.Google Scholar
41. Catts, VS, Catts, SV, Jablensky, A, Chandler, D, Weickert, CS, lavin, MF. Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia. World J Biol Psychiatry 2012;13:114–125.Google Scholar
42. Albayrak, Y, Unsal, C, Beyazyuz, M, Unal, A, Kuloglu, M. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:144–149.Google Scholar
43. Jorgensen, A, Broedbaek, K, Fink-Jensen, A et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res 2013;209:417–423.Google Scholar